Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

CTNM

Contineum Therapeutics Inc.

May 24 • 04:00PM ET

15.76

Dollar change -0.35
Percentage change -2.17	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF VTWO VTWG VTWV

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	55.11%	Shs Outstand	23.40M	Perf Week	1.68%
Market Cap	405.35M	Forward P/E	-	EPS next Y	-1.57	Insider Trans	0.00%	Shs Float	11.55M	Perf Month	-1.44%
Income	-	PEG	-	EPS next Q	-0.35	Inst Own	12.78%	Short Float	4.94%	Perf Quarter	-
Sales	-	P/S	-	EPS this Y	-4172.22%	Inst Trans	-	Short Ratio	4.79	Perf Half Y	-
Book/sh	-2.94	P/B	-	EPS next Y	14.32%	ROA	-	Short Interest	0.57M	Perf Year	-
Cash/sh	4.58	P/C	3.44	EPS next 5Y	-	ROE	-	52W Range	13.27 - 16.46	Perf YTD	2.34%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-4.27%	Beta	-
Dividend TTM	-	Quick Ratio	19.20	Sales past 5Y	0.00%	Gross Margin	-	52W Low	18.76%	ATR (14)	0.86
Dividend Ex-Date	-	Current Ratio	19.20	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	52.62	Volatility	3.53% 6.18%
Employees	31	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	28.00
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	-	Payout	-	Rel Volume	0.25	Prev Close	16.11
Sales Surprise	-	EPS Surprise	-218.39%	Sales Q/Q	-	Earnings	May 16 AMC	Avg Volume	119.16K	Price	15.76
SMA20	1.91%	SMA50	1.89%	SMA200	1.89%	Trades		Volume	29,290	Change	-2.17%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-30-24	Initiated	Stifel	Buy	$29
Apr-30-24	Initiated	RBC Capital Mkts	Outperform	$30
Apr-30-24	Initiated	Morgan Stanley	Overweight	$25

May-20-24 04:05PM	Contineum Therapeutics Announces Appointment of Troy Ignelzi to Board of Directors (Business Wire)
May-16-24 04:05PM	Contineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights (Business Wire)
Apr-04-24 09:02PM	Contineum Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

Contineum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on discovering and developing novel, oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. The company was founded by Daniel S. Lorrain on May 9, 2017 and is headquartered in San Diego, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CTNM

Contineum Therapeutics Inc.

Upgrade your FINVIZ experience